Jianing Fu, PhD


Academic Appointments

  • Instructor in Medical Sciences (in Medicine) at CUMC


  • Chinese


  • Female

Credentials & Experience

Education & Training

  • BS, 2008 Pharmaceutical Sciences, Peking University
  • MS, 2010 Chemical Biology, Peking University
  • Graduate Certificate, 2013 Clinical Investigation, University of South Florida
  • PhD, 2015 Cancer Biology (and Immunology), University of South Florida

Honors & Awards

·         2020 The Federation of Clinical Immunology Societies (FOCIS) Travel Award

·         2020 FCE (FOCIS Center of Excellence) Travel Award

·         2020 Top scored abstract, The Transplantation Society (TTS)

·         2019 Discovery Award, Department of Defense

·         2019 Transplant Forum Scholar Award, CUMC

·         2019 Medicine Grand Rounds, Fellow Research Presentation Award, CUMC

·         2018 Outstanding Oral Presentation Award, CCTI Research Day

·         2017/2018 International Transplantation Science Mentee-Mentor Awards, TTS

·         2017 Best Abstract, The Intestinal Rehabilitation & Transplant Association (IRTA)  

·         2016 Young Investigator Scientific Award, TTS

·         2015 Outstanding Thesis & Dissertation Award, University of South Florida (USF)

·         2012/2014 Abstract Achievement Awards, American Society of Hematology

·         2012/2013 Cancer Biology Travel Awards, USF

·         2012 Cancer Biology Student Organization Community Service Award, USF

·         2008 Excellent Volunteer in Beijing Olympic Games (Anti-doping Agency)

·         2006/2007/2008 Scholarships for Excellent Medical Students, Peking University


Dr. Jianing Fu is an Instructor in the Department of Medicine and principal investigator at the Columbia Center for Translational Immunology. Dr. Fu obtained her BS degree in Pharmaceutical Sciences and MS degree in Chemical Biology from Peking University (China), and received her PhD in Cancer Biology and Immunology from University of South Florida and H. Lee Moffitt Cancer Center in 2015. She did a Curricular Practical Training at Medical University of South Carolina to complete her doctoral education. Dr. Fu joined Columbia University in May 2015 to start her postdoctoral training and took the lead on several projects related to human organ transplantation under the role of an Associate Research Scientist. 
At Columbia, Dr. Fu’s laboratory is conducting translational research on decoding the graft-versus-host (GvH) and host-versus-graft (HvG) alloreactivity after human intestinal transplantation and lung transplantation. Her research also extends in investigating the phenotype and function of gut and lung hematopoietic stem cells and progenitors, with the ultimate goal of eliminating graft rejection by inducing long persistent blood mixed chimerism. Dr. Fu has established long term multidisciplinary collaboration with transplant surgeons, adult and pediatric physicians, pathologists, bioinformatic scientists and translational immunologists to perform cutting edge human transplantation studies.


2021-2023 R21, NIH/NIAID, AI166069-01. PI: Fu.
Direct costs: $275,000; Indirect costs: $170,500.
Immune profiling of gamma delta T cells after human intestinal transplantation. 

2021-2022 Nelson Faculty Development Award, CUMC. PI: Fu.
Total costs: $50,000 (including 10% indirect costs). 
Chimerism and immune repertoire of human gamma delta T cells after human lung transplantation.

2020-2022 Discovery Award, DoD, W81XWH-20-1-0159. PI: Fu.
Direct costs: $200,000; Indirect costs: $124,000. 
Single Cell Immune Profiling of Alloreactive T cells Locally and Systemically in Patients Receiving Intestinal Transplantation.

2020-2021 Nelson Faculty Development Award, CUMC. PI: Fu.
Total costs: $100,000 (including 10% indirect costs). 
Phenotypic and clonal tracking of human gamma delta T cells after human intestinal transplantation.

Selected Publications

  1. Fu J, Zuber J, Martinez M, Shonts B, Obradovic A, Wang H, Lau S-p, Xia A, Waffarn E, Frangaj K, Savage T, Simpson T, Yang S, Guo X, Miron M, Senda T, Rogers K, Rahman A, Ho S-h, Shen Y, Griesemer A, Farber D, Kato T, Sykes M. Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that are Maintained by a Circulating Pool. Cell Stem Cell. 2019 Feb 7;24(2):227-239.e8. PMCID: PMC6398344. (Commentary provided by Norma Sue Kenyon, PhD: “We Could Use More Tolerance: Role of Intestinal-Allograft- Derived Human Stem Cells”.)
  2. Fu J, Zuber J, Shonts B, Obradovic A, Wang Z, Frangaj K, Meng W, Rosenfeld A, Waffarn E, Liou P, Lau S-p, Savage T, Yang S, Rogers K, Danzl Nichole, Ravella S, Satwani P, Iuga A, Ho S-h, Griesemer A, Shen Y, Luning-Prak E, Martinez M, Kato T, Sykes M. Lymphohematopoietic graft-versus-host responses promote mixed chimerism in patients receiving intestinal transplantation. Journal of Clinical Investigation. 2021 Apr 15;131(8):e141698. doi: 10.1172/JCI141698. PMCID: PMC8062082
  3. Fu J, Sykes M. Emerging Concepts of Tissue-Resident Memory T cells in Transplantation. Transplantation. 2021 Nov 24. doi: 10.1097/TP.0000000000004000. Epub ahead of print. PMID: 34873129
  4. Obradovic A, Shen Y, Sykes M, Fu J*. Integrated Analysis Toolset for Defining and Tracking Alloreactive T-cell Clones After Human Solid Organ and Hematopoietic Stem Cell Transplantation. Software Impacts.2021 (10) 100142 (*Corresponding author)
  5. Fu J#, Khosravi-Maharlooei M, Sykes M. High throughput human T cell receptor sequencing: a new window into repertoire establishment and alloreactivity. Frontiers in Immunology.2021, 12:777756. #Co-first author.
  6. Savage T, Shonts B, Obradovic A, Dewolf S, Lau S-p, Zuber J, Simpson M, Berglund E, Fu J, Yang S, Robins H, Ho S-h, Tang Q, Turka L, Shen Y, Sykes M. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight. 2018;3(22):e124086.
  7. Weiner J, Zuber J, Shonts B, Yang S, Fu J, Martinez M, DeWolf S, Kato T, Sykes M. Long-term persistence of innate lymphoid cells in the gut after intestinal transplantation. Transplantation. 2017 101 (10), 2449-2454.
  8. Zuber J, Shonts B, Lau S-P, Obradovic A, Fu J, Yang S, Lambert M, Coley S, Weiner J, Thome J, DeWolf S, Farber D, Shen Y, Caillat-Zucman S, Bhagat G, Griesemer A, Martinez M, Kato T, Sykes M. Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. Science Immunology. 2016 1 (4), eaah3732. Cover Article.
  9. Fu J, Wang D, Yu Y, Heinrichs J, Wu Y, Schutt S, Kaosaard K, Liu C, Haarberg K, Bastian D, McDonald D, Anasetti C, and Yu X-Z. T-bet is critical for the development of acute graft-versus-host disease through controlling T-cell differentiation and function. J Immunol. 2015 Jan 1;194(1):388-97. PMCID: PMC4314960
  10. Fu J, Wu Y, Nguyen H, Heinrichs J, Schutt S, Liu Y, Liu C, Jin J, Anasetti C, and Yu X-Z. T-bet promotes acute graft-versus-host disease by regulating recipient hematopoietic cells in mice. J Immunol. 2016 Apr 1; 196 (7): 3168-3179. Cover Article. PMCID: PMC4799777
  11. Schutt S, Fu J*, Nguyen H, Bastian D, Heinrichs J, Wu Y, Sofi M, Liu C, McDonald D, Pidala J, Yu X-Z. Inhibition of BTK and ITK with Ibrutinib is Effective in the prevention of chronic graft-versus-host disease in mice. Plos One. 2015 10 (9), e0137641. *Co-first author. PMCID: PMC4562702
  12. Fu J, Heinrichs J, Yu X. Helper T-cell Differentiation in Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Arch Immunol Ther Exp. 2014 Aug; 62(4): 277-301.
  13. Wu Y, Fu J, Wang H J, Yu X-Z. Donor T cell repertoire profiling in recipient lymphoid and parenchyma organs reveals GVHD pathogenesis at clonal levels after bone marrow transplantation in mice. Frontiers in Immunology.2021, 12:778996.
  14. Fu J, Li J, Tan Q, Yin H, Xiong K, Wang T, Ren X, Zeng H. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Investigational New Drugs. 2011 29:627–636.
  15. Fu J, Wang J, Wang L, Wang L, Tang W, Cai G, Liu M, Zeng H. Drug efficacy and pharmacological action of ethaselen, a novel organoselenium antitumor drug. Journal of Chinese Pharmaceutical Sciences (English Version). 2010 19 (3): 163-168. PMCID: PMC5309752
  16. Wang L, Yang Z, Fu J, Yin H, Xiong K, Tan Q, Li J, Tang W, Yin J, Cai G, Liu M, Kehr S, Becker K, Zeng H, Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radical Biology and Medicine. 2012 Mar 1; 52(5): 898-908.
  17. Liu M, Fu J, Li J, Wang L, Tan Q, Peng Z, Zeng H, Preparation of tri-block copolymer micelles loading novel organoselenium anticancer drug BBSKE and study of tissue distribution of copolymer micelles by imaging in vivo method. International Journal of Pharmaceutics. 2010. May 31; 391(1-2): 292-304.
  18. Fu J, Zhang N, Chou J, Dong H-J, Lin S-F, Ulrich-Merzenich G, Chou T-C. Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy. 2016, 3(3):15-30.
  19. Zhang N, Fu J*, Chou T-C. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. Am J Cancer Res. 2016 6 (1), 97-104. *Co-first author. PMCID: PMC4759401
  20. Chou T-C, Shapiro T, Fu J, Chou J H, Ulrich-Merzenich G. Computerized quantification of drugs synergism in animal experiments or in clinical trials using only ten data points. Synergy. 2019, 9, [100049].